An Interactive Algorithm Tool: Assessment and Management of BTK Inhibitor Adverse Events
  • CME
  • CE

LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL
Use this Interactive Decision Support Tool to see strategies to assess and manage adverse events associated with BTK inhibitors from 5 renowned experts in hematologic malignancies.
Jeremy S. Abramson, MD, MMSc
Farrukh T. Awan, MD
Christopher R. Flowers, MD, MS
John P. Leonard, MD
Julie M. Vose, MD, MBA
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: September 10, 2019 Expiration: September 9, 2020
Interactive Decision Support Tool
Managing BTKi AEs
LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Safely initiate BTK inhibitor therapy in appropriate patients with MCL, MZL, CLL/SLL, and WM
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support quality of life and continuation of treatment
  • Explain to patients the importance of and provide strategies for optimal adherence to prescribed BTK inhibitors

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Jeremy S. Abramson, MD, MMSc

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from AbbVie, Amgen, Bayer, Celgene, EMD Serono, Genentech, Gilead Sciences, Janssen, Juno, Karyopharm, Merck, Novartis, Seattle Genetics, and Verastem.
Farrukh T. Awan, MD

Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program

Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh Awan, MD, has disclosed that he has received consulting fees from BluePrint Bio, Genentech, Gilead Sciences, and Sunesis; fees for non-CME/CE services from AbbVie and AstraZeneca; and funds for research support from Pharmacyclics.
Christopher R. Flowers, MD, MS

Director, Lymphoma Program
Professor
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Emory University
Atlanta, Georgia

Christopher R. Flowers, MD, MS, has disclosed that he has received consulting fees from AbbVie, Bayer, Denovo Biopharma, Gilead Sciences, Karyopharm, OptumRx, Pharmacyclics/Janssen, and Spectrum; has received funds for research support from AbbVie, Acerta, Celgene, Genentech/Roche, Gilead Sciences, Janssen, Millennium/Takeda, and TG Therapeutics; and has performed uncompensated consulting for Celgene and Genentech/Roche.
John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

John P. Leonard, MD, has disclosed that he has received consulting fees from ADC Therapeutics, AstraZeneca, Bayer, BeiGene, Celgene, Gilead Sciences, Kayropharm, Merck, MorphoSys, Nordic Nanovector, Roche/Genentech, Sandoz, and Sutro.
Julie M. Vose, MD, MBA

Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA, has disclosed that she has received consulting fees from AbbVie, Acerta/AstraZeneca, Epizyme, Janssen/Pharmacyclics, Kite, Karyopharm, Legend, Nordic Nanovector, Novartis, Roche, Vaniam Group, Sandoz, and Verastem and funds for research support from Acerta/AstraZeneca, Amgen, Bristol-Myers Squibb, Celgene, Incyte, Kite, Merck, Novartis, and Seattle Genetics.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with MCL, MZL, CLL/SLL, and WM.

Goal

The goal of this activity is to improve participants’ competence in minimizing and managing toxicity to maintain patients on BTK inhibitor therapy.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.0 contact hour may be earned for successful completion of this activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-19-106-H01-P. This program is designated for up to 1.00 contact hours (0.10 CEUs) of continuing pharmacy education credit.

Type of Activity Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 10, 2019, through September 09, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Enter patient details and submit case.
4. Review the patient case online or printed out.
5. Submit answers to the Clinical Implications questions and evaluation questions online.

You must respond to all Clinical Implications and evaluation questions to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Disclaimer

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “An Interactive Algorithm Tool: Assessment and Management of BTK Inhibitor Adverse Events,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices in monitoring and managing adverse events that can occur in patients with cancer treated with BTK inhibitor therapy.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “An Interactive Algorithm Tool: Assessment and Management of BTK Inhibitor Adverse Events” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2019 Clinical Care Options, LLC. All rights reserved.

Related Content

Download this Clinical Care Options (CCO) PDF resource guide on optimal team management of patients with chronic myeloid leukemia (CML).

Jorge Cortes, MD Jenny Dahl, PA person default Caitlin R. Rausch, PharmD Released: September 16, 2019

Downloadable clinician resource on CLL including current treatment algorithm and select ongoing phase III clinical trials

Andrew D. Zelenetz, MD, PhD Released: September 10, 2019

Caron A. Jacobson, MD: Latest data and clinical potential for using CAR T-cells plus checkpoint inhibitors to overcome CAR T-cell–resistant DLBCL

person default Caron A. Jacobson, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 10, 2019 Expiration: September 9, 2020

Expert commentary on nurses’ role in educating patients and caregivers about CAR T-cell therapy, from initial consult to monitoring for toxicities.

Alix Beaupierre, BSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 9, 2019 Expiration: September 8, 2020
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?